Recent CRIS News
- Curis to Present Updated Data from the TakeAim Leukemia Study • PR Newswire (US) • 05/10/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:30:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:02:29 PM
- Curis Provides First Quarter 2024 Business Update • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:00:00 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/05/2024 11:30:00 AM
- Curis to Present at Upcoming Healthcare Conferences in April • PR Newswire (US) • 04/04/2024 11:30:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:16:14 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/08/2024 09:36:50 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/08/2024 09:27:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/08/2024 09:01:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 01:01:02 PM
- Curis Provides Fourth Quarter 2023 Business Update • PR Newswire (US) • 02/08/2024 01:00:00 PM
- Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 • PR Newswire (US) • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 01:13:35 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 01/05/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 12/21/2023 09:00:47 PM
- Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study • PR Newswire (US) • 12/12/2023 01:00:00 PM
- Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Curis Announces Three Presentations at ASH • PR Newswire (US) • 12/06/2023 01:00:00 PM
- Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma • PR Newswire (US) • 12/05/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 12:03:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 12:01:51 PM
- Curis Provides Third Quarter 2023 Business Update • PR Newswire (US) • 11/02/2023 12:00:00 PM
- Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 • PR Newswire (US) • 10/26/2023 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM